Welcome to our dedicated page for UNITED THERAPEUTICS SEC filings (Ticker: UTHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
United Therapeutics Corporation filings document an operating biotechnology company with Nasdaq-listed common stock and a public benefit corporation structure. Recent 8-K reports cover quarterly and annual operating results, business updates, clinical-study announcements for Tyvaso and ralinepag, and capital actions such as share repurchase programs and accelerated share repurchase agreements.
Proxy materials describe board elections, director changes, executive compensation, shareholder voting matters and governance practices. The company’s formal disclosures also address its treprostinil-centered pulmonary arterial hypertension business, development programs in pulmonary and transplant-related medicine, and common-stock capital structure.
United Therapeutics Corporation reported that shareholders approved its 2026 Stock Incentive Plan at the 2026 Annual Meeting held on June 26, 2026. The plan is administered by the Board’s Compensation Committee and allows stock options, stock appreciation rights, restricted stock, restricted stock units, stock awards, and incentive bonuses.
The share pool under the 2026 Plan equals 1,500,000 new shares plus shares that remained available under the prior 2015 plan and certain shares from prior outstanding awards that are later canceled, forfeited, or settled in cash. As of June 26, 2026, 2,413,730 shares were available for future grant under the prior plan and 4,941,655 shares were subject to outstanding awards.
Shareholders also elected all director nominees and approved other matters described in the proxy statement. One key proposal received 25,872,075 votes for and 10,070,290 votes against, with 276,512 abstentions and 1,194,857 broker non-votes, indicating meaningful but not majority opposition.
United Therapeutics Corp Chairperson and CEO Martine Rothblatt reported option exercises and share sales in United Therapeutics common stock. She exercised stock options covering 9,500 shares at an exercise price of $135.42 per share and sold 9,500 shares in multiple open-market trades.
According to the footnotes, these transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. The plan will continue until the earlier of exercising 1,734,410 stock options that expire on March 15, 2027, or December 31, 2026. The reported sales were executed in multiple trades at weighted average prices between $543.12 and $555.31 per share.
In addition to direct holdings, various family trusts and a spouse account hold United Therapeutics common stock and stock options, including a family trust stock option position tied to 349,192 underlying shares at a $135.42 exercise price expiring on March 15, 2027.
United Therapeutics Corp Chairperson & CEO Martine Rothblatt reported a pre-planned option exercise and share sales. On June 24, 2026, she exercised stock options to acquire 9,500 shares of common stock at an exercise price of $135.4200 per share and sold 9,500 shares in multiple open-market transactions.
The sales, coded "S," occurred at weighted-average prices between roughly $545.46 and $553.48, as detailed in the footnotes. A footnote states these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of the exercise of 1,734,410 stock options expiring on March 15, 2027 or December 31, 2026. Separate entries show additional indirect holdings and stock options held through family trusts and by a spouse.
United Therapeutics Chairperson and CEO Martine Rothblatt reported exercising stock options and selling shares of common stock in a planned transaction. On June 23, 2026, she exercised 9,500 stock options at an exercise price of $135.42 per share and sold 9,500 shares of common stock in multiple open-market trades at weighted average prices around $540–$546 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which will continue until the earlier of exercising 1,734,410 stock options that expire on March 15, 2027, or December 31, 2026. Following the transactions, Rothblatt holds 40,513 shares of common stock directly, additional indirect common stock positions through various family trusts and a spouse account, and stock options on 349,192 underlying shares held indirectly through a family trust.
United Therapeutics Corp Chairperson and CEO Martine A. Rothblatt reported option exercises and related share sales in a Form 4. On June 22, 2026, she exercised stock options to acquire 9,500 shares of common stock at exercise prices of $146.03 and $135.42 per share, then sold 9,500 shares in multiple open-market transactions at prices generally around the mid‑$530s per share, all under a pre-arranged Rule 10b5‑1 trading plan adopted on November 7, 2025. Following these transactions, she directly holds 49,781 shares of common stock and has an indirect stock option position covering 349,192 underlying shares expiring on March 15, 2027. Additional common shares and options are held indirectly through various family trusts and by her spouse as described in the filing.
UNITED THERAPEUTICS Corp CFO and Treasurer James Edgemond exercised stock options for 8,750 shares of common stock at an exercise price of $146.03 per share and sold 8,750 shares in open‑market transactions on June 22, 2026. The sales were executed at weighted average prices around the mid‑$530s to low‑$540s per share pursuant to a pre‑arranged Rule 10b5‑1 trading plan entered into on October 31, 2025. Following these transactions, he directly holds 18,876 shares of UNITED THERAPEUTICS common stock.
United Therapeutics CFO and Treasurer James Edgemond exercised stock options for 10,000 shares of common stock at an exercise price of $146.03 per share and sold 10,000 shares in multiple open-market trades at prices between $533.25 and $549.17, all pursuant to a Rule 10b5-1 trading plan entered into on October 31, 2025. Following these transactions, he directly owned 18,876 shares of common stock and held 8,750 stock options.
United Therapeutics Corp Chairperson & CEO Martine Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share, then sold the same 9,500 shares in multiple open-market transactions on June 18, 2026.
The reported sales included trades such as 2,793 shares at $539.62 per share and 160 shares at $552.72 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which covers up to 1,734,410 stock options expiring on March 15, 2027 or runs until December 31, 2026, whichever comes first.
After these transactions, Rothblatt holds 49,533 shares of common stock directly, along with additional indirect holdings through various family trusts and her spouse.
United Therapeutics EVP & General Counsel Paul A. Mahon exercised and sold company stock in a planned transaction. On June 18, 2026, he exercised 8,300 stock options at an exercise price of $146.03 per share and sold the resulting 8,300 common shares in multiple open-market trades under a pre-arranged Rule 10b5-1 plan entered into on August 11, 2025. The sales occurred at weighted-average prices generally in the mid-$530s to mid-$550s per share, as detailed in the trade price ranges.
United Therapeutics Chairperson and CEO Martine Rothblatt reported an exercise-and-sale transaction in company stock. On June 17, 2026, she exercised stock options to acquire 9,500 shares of common stock at an exercise price of $146.03 per share and sold 9,500 shares of common stock in multiple open-market trades at weighted average prices in the $548–$556 per share range.
According to a footnote, these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which may continue until the earlier of exercising up to 1,734,410 stock options expiring on March 15, 2027 or December 31, 2026. The filing also lists additional indirect holdings in United Therapeutics common stock through various family trusts and the reporting person’s spouse.